| 胡十齐 封元清 雷晓宇 邹晴晴 王路瑶.GDP与CHOP方案治疗非特异性外周T 细胞淋巴瘤的临床对比研究[J].现代生物医学进展英文版,2016,16(32):6329-6331. |
| GDP与CHOP方案治疗非特异性外周T 细胞淋巴瘤的临床对比研究 |
| Clinical Comparative Study of GDP and CHOP Regimen in Treatment ofNonspecific Peripheral T Cell Lymphoma |
| |
| DOI： |
| 中文关键词: 非特异性外周T 细胞淋巴瘤 GDP 方案 CHOP方案 疗效 |
| 英文关键词: Nonspecific peripheral T cell lymphoma GDP regimen CHOP regimen Efficacy |
| 基金项目: |
|
| Hits: 798 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨GDP与CHOP 方案治疗非特异性外周T 细胞淋巴瘤的临床疗效，为临床治疗提供参考。方法：选择2013 年1 月
到2016 年1 月我院收治的非特异性外周T 细胞淋巴瘤患者80 例，随机分为GDP 组（n=40）和CHOP 组（n=40）。GDP组患者给
予GDP 治疗方案（顺铂+吉西他滨+强的松），CHOP组患者给予CHOP治疗方案（多柔比星+环磷酰胺+长春新碱+强的松），
两组患者均治疗6 个疗程。比较两组患者临床疗效和不良反应发生情况。结果：GDP组患者近期疗效总有效率为75.00%，明显高
于CHOP组的45.00%，差异具有统计学意义（P <0.05）。GDP组患者的无进展生存期（PFS）、总生存期（OS）分别为（9.69± 1.50）月
和（16.72± 3.06）月，明显大于CHOP组的（5.16± 1.38）月和（10.98± 3.37）月，差异具有统计学意义（P <0.05）。GDP组患者恶心呕
吐的发生率为72.50%，明显低于CHOP 组的97.50%，差异具有统计学意义（P <0.05）。结论：GDP 方案治疗非特异性外周T 细胞
淋巴瘤的临床疗效明显优于CHOP 方案，且不良反应发生率低，值得在临床上推广应用。 |
| 英文摘要: |
| Objective:To study the clinical efficacy of GDP and CHOP in the treatment of nonspecific peripheral T cell
lymphoma,and to provide reference for clinical treatment.Methods:Selected 80 cases of patients with nonspecific peripheral T cell
lymphoma who treated in our hospital from January 2013 to January 2016,and randomly were divided into GDP group(n=40) and CHOP
group (n=40).The GDP group were treated with the GDP regimen (cisplatin+gemcitabine+prednisone), and the CHOP group were
treatment with the CHOP regimen (adriamycin+cyclophosphamide+vincristine+prednisone), the patients in two groups were treated for
six courses. Compared the clinical efficacy and adverse reactions of patients in the two groups.Results:The total effective rate in the
short-term of the GDP group was 75.00%, which was significantly higher than 45.00% of the CHOP group, the difference was
statistically significant (P<0.05). The progression-free survival (PFS) and overall survival (OS) of the GDP group were (9.69± 1.50)
months and (16.72± 3.06) months respectively, which were significantly higher than (5.16± 1.38) months and (10.98± 3.37) months of
the CHOP group,the differences were statistically significant(P<0.05). The incidence of nausea and vomiting in GDP group was 72.50%,
which was significantly lower than 97.50% of CHOP group, and the difference was statistically significant (P<0.05).Conclusion:The
clinical efficacy of GDP regimen on the treatment of patients with nonspecific peripheral T cell lymphoma is superior to that of traditional
CHOP regimen, and have less adverse reactions, which is worthy application in clinic. |
|
View Full Text
View/Add Comment Download reader |
| Close |
